Aripiprazole Tablet
Product Images NDC 68071-3848

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 68071-3848). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3848 3)

This is a product description for Aripiprazole 5mg tablets. It contains important information such as the manufacturer's label, NDC codes, lot numbers, expiration dates, and the GTIN. The warning on the label cautions users to keep the medication out of reach of children. It also provides instructions to call a doctor for medical advice regarding side effects and how to report side effects to the FDA. Additionally, it specifies the controlled temperature for storing the medication at 68-77°F.*

FDA Label Image

Camber-logo (Camber Logo)

FDA Label Image

Figure1 (Figure1)

This text provides information on the effect of various drugs on the pharmacokinetics of aripiprazole. It includes data on the PK changes and 90% confidence intervals for aripiprazole when co-administered with different types of drugs such as CYP3A4 inhibitors like ketoconazole, CYP2D6 inhibitors, antiepileptic drugs like carbamazepine, and gastric acid blockers like famotidine. Additionally, it mentions potential drug interactions with lorazepam. The text seems to present a comparative analysis of the changes in aripiprazole exposure relative to a reference scenario without interacting drugs.*

FDA Label Image

Figure2 (Figure2)

FDA Label Image

Figure3 (Figure3)

FDA Label Image

Figure4 (Figure4)

This text provides information on special populations in a study, including individuals with cvpads, poor metabolizer ALC, different genders, ages, and varying degrees of hepatic and renal impairment. The text also mentions a change chart related to aripiprazole.*

FDA Label Image

Figure5 (Figure5)

FDA Label Image

Figure6 (Figure6)

FDA Label Image

Figure7 (Figure7)

FDA Label Image

Figure8 (Figure8)

FDA Label Image

Figure9 (Figure9)

This text provides information on the least squares mean change in YGTSS (Yale Global Tic Severity Scale) total TIC (Tourette's syndrome) score attributed to different treatments, including Abilify Low, Abilify High, and Placebo. The data indicates the change in the YGTSS total TIC score from baseline for these treatment groups.*

FDA Label Image

Structure-1 (Structure 1)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.